Why EXACT Sciences Corporation Is Rising Today
Shares of EXACT Sciences (NASDAQ: EXAS), a company focused on colon-cancer detection, rose as much as 13% in early morning trading on Wednesday in response to reporting better-than-expected second-quarter results.
Here's a review of the key highlights from the period that have traders feeling giddy today:
The solid quarterly performance allowed management to significantly raise its guidance for the year. Management now expects to complete at least 550,000 Cologuard tests during 2017. That's quite a big jump from the 470,000 tests that management had forecasted just three months ago.
Source: Fool.com
Exact Sciences Stock
€41.04
-0.010%
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Exact Sciences.
With a target price of 82 € there is a hugely positive potential of 99.83% for Exact Sciences compared to the current price of 41.04 €.
